Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol
NCT00006071 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2008-03-04
Summary
Cells in the lining of blood vessels produce various substances that cause the vessels to dilate (relax) and constrict (tighten), thereby regulating blood flow. In patients with high blood pressure and high cholesterol, the blood vessels do not dilate properly. This study will investigate the effects of rosiglitazone-a drug used to improve the action of insulin in diabetic patients-on blood flow by examining its effects on endothelin (a substance that causes vessel constriction), and other substances produced by the vessel-lining cells.
Adults with blood pressure recordings of 140/90 mmHg or higher on at least three separate days or with a blood cholesterol level of at least 240 mg/dl may be eligible for this study. Candidates will be screened with a medical history and physical examination, blood pressure recordings, blood and urine tests.
This "crossover" study involves two separate treatment periods; that is, participants will take either rosiglitazone or placebo (an inactive look-alike pill) once a day for 8 weeks, then no drug for 4 weeks, and then the alternative treatment for the next 8 weeks. Patients will continue to take their high blood pressure medicines during the first 6 weeks of each treatment period. They will stop the medication 2 weeks before the following procedures, which are done at the end of each 8-week treatment period:
Strain gauge plethysmography-A small catheter is placed through a needle into an artery at the bend of the arm for measuring blood pressure and drawing blood samples during the study. Pressure cuffs are placed on the wrist and upper arm, and a strain gauge (a rubber band device) is placed around the forearm to measure forearm blood flow. When the cuffs are inflated, blood flows into the arm, stretching the strain gauge at a rate proportional to the flow, and the measurement is recorded.
Small doses of four drugs-acetylcholine, bradykinin, sodium nitroprusside and BQ-123-are given through the catheter. Acetylcholine slows the heart rate. Bradykinin stimulates the release of a substance that causes blood vessels to dilate and can lower blood pressure. Sodium nitroprusside causes blood vessels to dilate and is used to treat high blood pressure and heart failure. BQ-123 blocks the blood vessel-constricting activity of endothelin.
Brachial ultrasound reactivity study-A baseline ultrasound image (picture produced using sound waves) of the brachial artery (artery located at the bend of the arm) is taken and blood flow measurements are recorded. Then, a pressure cuff is placed around the upper forearm, inflated for 5 minutes to stop blood flow to the forearm, and then released. Images of the artery and flow measurements are repeated. After a 15-minute rest, new baseline images are taken and flow measurements obtained. A small amount of nitroglycerin is then sprayed under the tongue and after 3 minutes, blood flow measurements and brachial artery images are recorded once more.
Conditions
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2000-07-31
- Completion
- 2001-03-31
Countries
- United States
Study Locations
More Related Trials
-
Effects of Sodium Chloride or Its Substitute Salt Potassium Chloride on Vascular Function
NCT05970601 ·Status: COMPLETED ·Phase: NA
-
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects
NCT05905068 ·Status: COMPLETED ·Phase: PHASE1
-
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
NCT03273972 ·Status: COMPLETED ·Phase: NA
-
Gene-by-Stress Interactions in Intervention Studies Significance
NCT03011645 ·Status: TERMINATED ·Phase: PHASE1
-
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
NCT00461630 ·Status: COMPLETED ·Phase: PHASE3
-
A Second Study to Determine the Effect of GSK256073A on HVTs
NCT00551694 ·Status: COMPLETED ·Phase: PHASE1
-
Lipid Efficacy/Tolerability Study (0524A-020)
NCT00269204 ·Status: COMPLETED ·Phase: PHASE3
-
Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
NCT00300365 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
NCT00769132 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol
NCT00927459 ·Status: TERMINATED ·Phase: PHASE1
-
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
NCT00071266 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of MK0524A on Cholesterol Levels (0524A-048)
NCT00536510 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Niacin Therapy on Lipoprotein Composition and Function
NCT02322203 ·Status: COMPLETED ·Phase: NA
-
The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk
NCT01293162 ·Status: COMPLETED
-
Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease
NCT01391377 ·Status: TERMINATED ·Phase: NA
-
Coronary Drug Project
NCT00000482 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
NCT00404001 ·Status: COMPLETED ·Phase: PHASE2
-
Optimizing Statin Tratment in People Living With Diabetes
NCT04320719 ·Status: COMPLETED
-
Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL
NCT01450410 ·Status: TERMINATED ·Phase: PHASE4
-
the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
NCT06132360 ·Status: COMPLETED ·Phase: PHASE1
-
Statin Compliance of Patients With Non-insulin-dependent Diabetes
NCT04007133 ·Status: TERMINATED
-
Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients
NCT00639080 ·Status: COMPLETED
-
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
NCT04369664 ·Status: COMPLETED ·Phase: PHASE4
-
A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
NCT00608699 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
NCT01979601 ·Status: COMPLETED ·Phase: PHASE1